SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Francis PA, Rigas JR, Kris MG, et al. Phase II of docetaxel in patients with Stage III and IV non-small-cell lung cancer. J Clin Oncol. 1994; 12: 12321237.
  • 2
    Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000; 18: 20952103.
  • 3
    Fosella FV, DeVore R, Kerr RN, et al. Randomized Phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol. 2000; 18: 23542362.
  • 4
    Anderson H, Lund B, Bach F, et al. Single-agent activity of weekly gemcitabine in advanced non-small cell carcinoma: a Phase II study. J Clin Oncol. 1994; 12: 18211826.
  • 5
    Carmichael J, Possinger K, Phillip P, et al. Advanced breast cancer: a Phase II trial with gemcitabine. J Clin Oncol. 1995; 13: 27312736.
  • 6
    Ravdin PM, Burris HA III, Cook G, et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol. 1995; 13: 28792885.
  • 7
    Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15: 24032413.
  • 8
    Rougier P. Docetaxel delivers new management opportunities for gastrointestinal carcinomas. Anticancer Drugs. 1995; 6(Suppl 4): 2529.
  • 9
    Stadler WM, Kuzel T, Roth B, et al. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol. 1997; 15: 33943398.
  • 10
    McCaffery JA, Hilton S, Mazumdar M, et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol. 1997; 15: 18531857.
  • 11
    Shapiro JD, Millward MJ, Rischin D, et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol. 1996; 63: 8993.
  • 12
    Francis P, Schneider J, Hann L, et al. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol. 1994; 12: 23012308.
  • 13
    Plunket W, Huang P, Searcy CE, et al. Gemcitabine: preclinical pharmacology and mechanism of action. Semin Oncol. 1996; 23(Suppl 10): 315.
  • 14
    Hennequinn C, Giocanti N, Favaudan V. S-phase specificity of cell killing by docetaxel (Taxotere) in synchronized HeLa cells. Br J Cancer. 1995; 71: 11941198.
  • 15
    Pawinski A, Louwerens M, Tonelli D, et al. A Phase I study of Taxotere (T) and Gemzar (G) in patients with advanced solid tumors [abstract]. Proc Am Soc Clin Oncol. 1998; 17: 249a.
  • 16
    Spiridonidis CH, Laufman LR, Jones JJ, et al. Weekly gemcitabine (gem) combined with monthly docetaxel (doc) in patients (pts) with advanced malignancies. A Phase I trial. Ann Oncol. 2001; 12: 8994.
  • 17
    Rebattu P, Pujol JL, Ardiet C, et al. Combination of docetaxel (T) and gemcitabine (G) in patients with inoperable or metastatic non-small cell lung cancer (NSCLC), a Phase I study. Preliminary results on an active regimen [abstract]. Amsterdam: Tenth NCI-EORTC Symposium on New Drugs in Cancer Therapy, June, 1998.
  • 18
    Georgoulias V, Kouroussis C, Andoulakis N, et al. Docetaxel (Taxotere) and gemcitabine in the treatment of non-small cell lung cancer: preliminary results. Semin Oncol. 1977; 24(Suppl 14): S2225.
  • 19
    Georgoulias V, Kouroussis C, Andoulakis N, et al. Front-line treatment of advanced non-small cell lung cancer (NSCLC) with docetaxel (D) and gemcitabine (G): a multicenter Phase II trial. J Clin Oncol. 1999; 17: 914920.
  • 20
    Davis TH, Rigas J, Maurer H, et al. Unique two week schedule of docetaxel and short infusion gemcitabine in solid tumors: preliminary results of a Phase I trial [abstract]. Proc Am Soc Clin Oncol. 1998; 17: 239a.
  • 21
    Davis TH, Rigas J, Maurer H, et al. Phase I trial of docetaxel and short infusion gemcitabine given every two weeks for advanced solid tumors [abstract]. Ann Oncol. 1998; 9(Suppl 4): S134.
  • 22
    Briasoulis E, Karavasilis V, Anastasopoulos D, et al. Weekly docetaxel in minimally pretreated cancer patients: a dose escalation study focused on feasibility and cumulative toxicity of long term administration. Ann Oncol. 1999; 10: 701706.
  • 23
    Hainsworth JD, Burris HA, Erland JB, et al. Phase I of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol. 1998; 16: 21642168.
  • 24
    Luck HJ, Galaubitz M. Phase I study of weekly docetaxel (Taxotere) in heavily pretreated breast cancer patients. Eur J Cancer. 1997; 33: S158.
  • 25
    Lilenbaum RC, Schwartz MA, Seigel L, et al. Phase II trial of weekly docetaxel in second-line therapy for nonsmall cell lung carcinoma. Cancer. 2001; 92: 21582163.
  • 26
    Hainsworth JD, Burris HA, Erland JB, et al. Phase I of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol. 1998; 16: 21642168.
  • 27
    Valero V, Holmes FA, Walters RS, et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol. 1996; 14: 16721678.
  • 28
    Dunsford ML, Mead GM, Bateman AC, Cook T, Tung K. Severe pulmonary toxicity with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma. Ann Oncol. 1999; 10: 943947.
  • 29
    Loëffler T, Freund W, Droge C, Hausamen T. Activity of weekly taxotere (TXT) in patients with metastatic breast cancer [abstract]. Proc Am Soc Clin Oncol. 1998; 17: 113a.
  • 30
    Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981; 47: 207214.
  • 31
    National Cancer Institute. Common toxicity criteria, version 2.0. Bethesda: National Cancer Institute, 1998.
  • 32
    Millward MJ, Zaleberg J, Bishop JF, et al. Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small cell lung cancer. J Clin Oncol. 1997; 15: 750758.
  • 33
    Shepherd FA, Burkes R, Comier Y, et al. Phase I dose-escalation trial of gemcitabine and cisplatin for advanced non-small-cell lung cancer: usefulness of mathematic modeling to determine maximum-tolerable dose. J Clin Oncol. 1996; 14: 16561662.
  • 34
    Georgoulias V, Papadakis E, Alexopolous A, et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomized multicenter trial. Lancet. 2001; 357: 14781484.
  • 35
    Schlosser NJJ, Richel DJ, van Zanwijk N,et al. Phase I study of docetaxel and gemcitabine combination chemotherapy in chemotherapy naïve patients with advanced or metastatic non small lung cancer [abstract]. Proc Am Soc Clin Oncol. 1998; 17: 499a.
  • 36
    Fossella FV, Lee JS, Murphy WK, et al. Phase II study of docetaxel for recurrent or metastatic non-small cell lung cancer. J Clin Oncol. 1994; 12: 12381244.
  • 37
    Zalcerg J, Milward M, Bishop J, et al. Phase II study of docetaxel and cisplatin in advanced non-small cell lung cancer. J Clin Oncol. 1998; 16: 19481953.
  • 38
    Nabholtz JM, Mackey JR, Smylie M, et al. Phase II study of taxotere (docetaxel), doxorubicin and cyclophosphamide (TAC) in the treatment of metastatic breast cancer [abstract]. Proc Am Soc Clin Oncol. 1997; 16: 148a.
  • 39
    Burris HA. Optimal use of docetaxel (Taxotere): maximizing its potential. Anticancer Drugs. 1996; 7(Suppl 2): 2528.
  • 40
    Van Oosterom AT, Schrivjiers D. Docetaxel (Taxotere), a review of preclinical and clinical experience. Part II: clinical experience. Anticancer Drugs. 1995; 6: 356368.
  • 41
    Bhargava P, Marshall JL, Fried K, et al. Phase I and pharmacokinetics study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer. Cancer Chem Pharm. 2001; 48: 95103.
  • 42
    Frasci G, Comella P, D'Aiuto G, et al. Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: a parallel dose-finding study. Southern Italy Cooperative Oncology Group (SIGOG). Ann Oncol. 2000; 11: 367371.
  • 43
    Ryan DP, Lynch TJ, Grossbard ML, et al. A Phase I study of gemcitabine and docetaxel patients with metastatic solid tumors. Cancer. 2000; 88: 180185.
  • 44
    Rischin D, Boyer M, Smith J, et al. A Phase I trial of docetaxel and gemcitabine in patients with advanced cancer. Ann Oncol. 2000; 11: 421426.
  • 45
    Hejna M, Kornek GV, Raderer M, Ulrich-Pur H, Fiebiger WCC, Marosi L. Treatment of patients with advanced non-small cell lung cancer using docetaxel and gemcitabine plus granulocyte-colony stimulating factor. Cancer. 2000; 89: 516522.
  • 46
    Pavikis N, Bell DR, Millward MJ, Levi JA. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer. 1997; 80: 286291.
  • 47
    Merad M, Le Cesne A, Baldeyrou P, et al. docetaxel and interstitial pulmonary injury. Ann Oncol. 1997; 8: 191194.
  • 48
    Hainsworth JD, Burris HA, Greco A. Weekly docetaxel as a single agent and in combination with gemcitabine in elderly and poor performance status patients with advanced non-small cell lung cancer. Semin Oncol. 2000; 28(Suppl 9): 2125.
  • 49
    Kououssis C, Agelaki S, Mavroudis D, et al. A dose escalation study of weekly docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2000; 46: 488492.
  • 50
    Aventis Pharmaceutical Products, Inc. Taxatere package insert. Bridgewater, NJ: Aventis Pharmaceutical Products, Inc., 2000.
  • 51
    Harris J, Morrow M, Norton L. Malignant tumors of the breast. In: DeVitaVT, HellmanS, RosenbergSA, editors. Cancer,principles and practice of oncology, 5th ed. Philadelphia: Lippincott-Raven, 1997: 15571616.
  • 52
    Gilewski T, Norton L. Cytokines of neoplasia. In: MendelsonJ, HowleyP, IsraelMA, et al., editors. Molecular basis of cancer. Philadelphia: Saunders, 1995: 143159.
  • 53
    Norton L. Adjuvant breast cancer therapy: current status and future strategies. Growth kinetics and the improved drug therapy of breast cancer. Semin Oncol. 1999; 26(1 Suppl 3 ): 14.
  • 54
    Hainsworth JD, Burris HA, Litchy S, Morrissey LH, Bradof JE, Greco FA. Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. A Minnie Pearl Cancer Research Network Phase II trial. Cancer. 2000; 89: 328333.
  • 55
    Burstein HJ, Manola J, Younger J, et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol. 2000; 18: 12121219.
  • 56
    Akerley W, Choy H, Safran H, et al. Weekly paclitaxel in patients with advanced lung cancer. Semin Oncol. 1997; 24: 1013.
  • 57
    Fennelly D, Aghajanian C, Shapiro F, et al. Phase I and pharmacologic study of paclitaxel administration weekly in patients with relapsed ovarian cancer. J Clin Oncol. 1997; 15: 187192.
  • 58
    Hahn SM, Liebman JE, Cook J, et al. Taxol in combination with doxorubicin or etoposide. Cancer. 1993; 72: 27052711.
  • 59
    Theodossiou C, Cook JA, Fisher J, et al. Interaction of gemcitabine with paclitaxel and cisplatin in human tumor cell lines. Int J Oncol. 1998; 12: 217222.
  • 60
    Zoli W, Ricotti L, Barzanti L, et al. Schedule dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines. Int J Cancer. 1999; 80: 413416.
  • 61
    Zoli W, Ricotti L, Dal Susino M,et al. Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer. Br J Cancer. 1999; 81: 609615.